当前位置: 首页 > 医疗版 > 疾病专题 > 呼吸内科 > 其它 > 呼吸衰竭 > 临床治疗
编号:12078676
纳络酮治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的53例临床观察
http://www.100md.com 2011年4月1日 《中国中医药咨讯》 2011年第7期
纳络酮治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的53例临床观察
纳络酮治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的53例临床观察

     【摘要】目的:探讨纳洛酮治疗慢性阻塞性肺疾病(COPD)合并II型呼吸衰竭的疗效。方法:将106例COPD合并II型呼吸衰竭患者随机分成两组,对照组给予常规治疗,治疗组在对照组治疗方法基础上加用纳洛酮治疗。结果:治疗组治疗前后在临床症状、体征、肺功能、血气分析等各项观察指标的改善上明显优于对照组,差异具有统计学意义(P<0. 05),两组未见明显不良反应。结论:纳洛酮治疗COPD合并II型呼吸衰竭患者是一种安全有效的方法,值得临床推广应用。

    【关键词】纳络酮;慢性阻塞性肺疾病;Ⅱ型呼吸衰竭;疗效

    Naloxone Treatment of Chronic Obstructive Pulmonary Disease with respiratory failure Ⅱ Clinical Observation of 53 cases

    【Abstract】Objective: To investigate the naloxone treatment of chronic obstructive pulmonary disease (COPD) combined type II respiratory failure. Methods: 106 cases of type II respiratory failure combined COPD patients were randomly divided into two groups, control group received conventional therapy, the treatment group therapy in the control group based on the use of naloxone treatment. Results: before and after treatment, clinical symptoms, signs, pulmonary function, blood gas analysis and other indicators of improvement observed is obviously better than the control group, the difference was statistically significant (P <0.05), the two groups no significant adverse reaction. Conclusions: Naloxone treatment of COPD patients with respiratory failure combined II is a safe and effective method, is worthy of clinical application. ......

您现在查看是摘要页,全文长 5935 字符